GNMX Aevi Genomic Medicine Inc.

1.28
+0.04  (3%)
Previous Close 1.24
Open 1.35
Price To book 2.67
Market Cap 47500855
Shares 37,110,043
Volume 743,841
Short Ratio 3.58
Av. Daily Volume 206,141

SEC filingsSee all SEC filings

  1. 8-K - Current report 171142909
  2. SC 13D - General statement of acquisition of beneficial ownership 171141056
  3. DEF 14A - Other definitive proxy statements 171076812
  4. PRE 14A - Other preliminary proxy statements 171055199
  5. 8-K - Current report 171034058

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 trial to be initiated 2H 2017 with data due mid-2018.
AEVI-001 (NFC-1)
ADHD - 9-Gene subset
Phase 1/2 data due around end of 2017.
AEVI-002 (Anti-LIGHT mAb)
Pediatric onset Crohn's disease
Phase 1/2 commencement of enrollment announced January 31, 2017.
AEVI-001 (NFC-1)
22q11.2 Deletion Syndrome
Phase 2/3 data released March 20, 2017 - primary endpoint not met. Subset of data released April 20, 2017 - to be presented April 21, 2017.
NFC-1 - SAGA
mGluR mutation positive ADHD

Latest News

  1. Aevi Genomic Medicine Announces Completion of $28 Million Private Placement
  2. Is Aevi Genomic Medicine Inc (GNMX) Undervalued?
  3. Aevi Genomic Medicine to Present at the Rodman & Renshaw 19th Annual Global Investment Conference
  4. GNMX: AEVI-001 Data Mid-2018, Next Value Inflection Point?
  5. Aevi Genomic Medicine Announces Agreement for $28 Million Private Placement
  6. Aevi Genomic Medicine Reports Second Quarter 2017 Financial Results
  7. Aevi Genomic Medicine to Present at the JMP Securities Life Sciences Conference
  8. Blog Coverage: Aevi Genomics Announces Phase 2 Clinical Trial and Reports Q1 2017 Results
  9. Aevi Genomic Medicine Announces Plans to Initiate Phase 2 Clinical Trial to Confirm Genetic Responders to AEVI-001 and First Quarter 2017 Operating Results
  10. Investor Network: Aevi Genomic Medicine, Inc. to Host Earnings Call
  11. Aevi Genomic Medicine to Host Conference Call to Announce First Quarter and Discuss Recent Business Updates
  12. Aevi Genomic Medicine to Present at the 42nd Annual Deutsche Bank Health Care Conference
  13. GNMX: New SAGA Data May Be Just What The Doctor Ordered
  14. Aevi Genomic Medicine Presents Updated Results from SAGA Trial of AEVI-001 at the 6th World Congress on ADHD
  15. Aevi Genomic Medicine to Present Updated Results from SAGA Trial of AEVI-001 at the 6th World Congress on ADHD
  16. Aevi Genomic Medicine to Present at the 16th Annual Needham Healthcare Conference
  17. GNMX: SAGA Misses Primary Endpoint But Data Warrants Optimism
  18. Today's Research Reports on Stocks to Watch: Pulmatrix and Aevi Genomic Medicine
  19. Why Aevi Genomic Medicine Got Crushed Today
  20. Aevi Genomic Medicine Provides Top-line Results from the SAGA Trial of AEVI-001

SEC Filings

  1. 8-K - Current report 171142909
  2. SC 13D - General statement of acquisition of beneficial ownership 171141056
  3. DEF 14A - Other definitive proxy statements 171076812
  4. PRE 14A - Other preliminary proxy statements 171055199
  5. 8-K - Current report 171034058
  6. 8-K - Current report 171025325
  7. 8-K - Current report 171019720
  8. 8-K - Current report 171019026
  9. 10-Q - Quarterly report [Sections 13 or 15(d)] 171018144
  10. S-8 - Securities to be offered to employees in employee benefit plans 171015186